Profile

Quethera Ltd

Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. The initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. Quethera is working alongside world leaders in the glaucoma field to design clinical trials capable of examining the efficacy and safety of novel therapies in patients who lose parts of their visual field at an accelerated rate (fast-progressors). The company has expertise in gene therapeutic design and development sufficient to progress its pipeline through preclinical testing and into clinical development.

On 10 August 2018, Japanese Astellas Pharma bought privately-owned biotech Quethera for $109 million, gaining access to its gene therapy focused on developing novel treatments for glaucoma and eye disorders.

Midven’s UK Innovation & Science Seed Fund (UKI2S) was the founding investor with follow-on, co-investment from Cambridge Enterprise.

Under the terms of the purchase agreement, Astellas may pay up to $109 million in aggregate consideration (upfront and contingent payments) to Quethera shareholders to acquire Quethera.  The full announcement may be found here.

 

 

 

Status exits

Associated Fund UK Innovation & Science Seed Fund

Sector Medical / Biotechnology

Website www.quethera.com/

Associated Team Members

Relevant News

Astellas Announces Acquisition of Quethera

Acquisition furthers Astellas’ commitment to innovation in ophthalmology with addition of novel gene therapy program…

read more

Quethera Announces Seed Financing To Develop Gene Therapy Aimed At Preventing Blindness In Glaucoma Patients

24 September 2015 Quethera, a gene therapy company developing a treatment for glaucoma that could…

read more

Quethera will present pre-clinical efficacy data at the Association for...

Quethera will present pre-clinical efficacy data at the Association for Research in Vision and...

read more

Blog

UKI2S biotech company Quethera acquired for $109m

On 10 August 2018, Japanese Astellas Pharma bought privately-owned biotech Quethera for $109 million, gaining…

read more

More Companies in Medical / Biotechnology

Your browser is out-of-date!

Update your browser to view this website correctly.Update my browser now

×